Physician profile
Marc Matozzo
NPI 1437156098
$1,890.51
in general payments reported to CMS, 2019-2025
31 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $275 · 2021: $344 · 2022: $409 · 2023: $52.19 · 2024: $289 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $414.22 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.32 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $151.13 | 2019-2024 | Trelegy Ellipta |
| Collegium Pharmaceutical, INC. | $115.19 | 2021 | |
| Lilly USA, LLC | $102.07 | 2020-2025 | Mounjaro, Jardiance |
| Abbvie INC. | $89.31 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.66 | 2019-2021 | |
| Amarin Pharma, INC. | $75.84 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $69.70 | 2019-2022 | |
| Astellas Pharma US INC | $65.14 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $64.24 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $58.52 | 2019-2025 | Zoryve |
| Scilex Pharmaceuticals INC. | $32.15 | 2019 | |
| Lundbeck LLC | $31.05 | 2025 | Rexulti |
| Hikma Pharmaceuticals USA | $30.15 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $28.56 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $24.91 | 2025 | Rexulti |
| Almatica Pharma LLC | $24.35 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.22 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.75 | 2022 | |
| Hologic Sales and Service, LLC | $22.04 | 2025 | Aptima |
| Abbott Laboratories | $21.96 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.49 | 2022 | |
| Arbor Pharmaceuticals, INC. | $18.71 | 2021 | |
| Seqirus USA INC | $17.23 | 2020 | |
| Pfizer INC. | $15.93 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $15.80 | 2021 | |
| Protega Pharmaceutials INC | $14.50 | 2023 | Roxybond |
| Astrazeneca Pharmaceuticals LP | $14.10 | 2019 | |
| Cipher Pharmaceuticals US LLC | $13.85 | 2025 | Natroba, Spinosad |
| Merck Sharp & Dohme LLC | $12.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Matozzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.